Universität zu Köln

Herden, Jan ORCID: 0000-0002-1667-5200, Heidegger, Isabell, Paffenholz, Pia and Porres, Daniel (2015). Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine. Oncol. Res. Treat., 38 (12). S. 654 - 666. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Abstract

The approval or clinical evaluation of several new agents - cabazitaxel, abiraterone acetate, enzalutamide, sipuleucel-T, and radium-223 - has significantly changed the management of patients with metastatic castration-resistant prostate cancer (mCRPC) prior to or after docetaxel-based chemotherapy. All of these agents have resulted in a significant survival benefit as compared to their control group. However, treatment responses might differ depending on the associated comorbidities and the extent and biological aggressiveness of the disease. Furthermore, treatment-associated side effects differ between the various drugs. As new drugs become approved, new treatment strategies and markers to best select which patients will best respond to which drug are needed. It is the aim of the current article to i) summarize the data of established treatment options in mCRPC, ii) highlight new developments in medical treatment, iii) provide clinically useful algorithms for the daily routine, and iv) point out future developments in medical treatment. (C) 2015 S. Karger GmbH, Freiburg

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Herden, Jan UNSPECIFIED orcid.org/0000-0002-1667-5200 UNSPECIFIED Heidegger, Isabell UNSPECIFIED UNSPECIFIED UNSPECIFIED Paffenholz, Pia UNSPECIFIED UNSPECIFIED UNSPECIFIED Porres, Daniel UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-385446
DOI:	10.1159/000442030
Journal or Publication Title:	Oncol. Res. Treat.
Volume:	38
Number:	12
Page Range:	S. 654 - 666
Date:	2015
Publisher:	KARGER
Place of Publication:	BASEL
ISSN:	2296-5262
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MITOXANTRONE PLUS PREDNISONE; PHASE-III TRIAL; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; DOCETAXEL RECHALLENGE; INCREASED SURVIVAL; PROGNOSTIC MARKER; ENZALUTAMIDE Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/38544